Loading...
XWAR
SPH
Market cap245mUSD
Jun 19, Last price  
7.50PLN
1D
0.00%
1Q
0.00%
Name

Sopharma AD

Chart & Performance

D1W1MN
XWAR:SPH chart
P/E
5.48
P/S
0.20
EPS
0.63
Div Yield, %
3.30%
Shrs. gr., 5y
5.53%
Rev. gr., 5y
10.69%
Revenues
2.61b
+22.58%
644,731,000688,579,000762,689,000840,517,000874,984,000877,085,0001,017,105,0001,179,143,0001,281,587,0001,438,826,0001,603,310,0001,662,992,0001,887,947,0002,129,097,0002,609,782,000
Net income
134m
+74.97%
38,404,00035,196,00029,248,00020,178,00021,314,00050,638,00039,998,00028,343,00086,994,00029,805,00089,496,00071,121,00095,207,00076,310,000133,522,000
CFO
19m
-75.82%
38,404,00035,196,00029,248,00020,178,00021,314,00050,638,00039,998,00028,343,000-128,444,000-179,411,000-75,963,000124,622,00045,033,00076,728,00018,550,000
Dividend
Dec 18, 20250.18938 PLN/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Sopharma AD, an international pharmaceutical company founded in Sofia, Bulgaria, in 1933, specializes in the research, development, manufacturing, and commercialization of a wide array of healthcare products. Its offerings span medicinal substances, finished drug formulations, veterinary vaccines, infusion solutions, and disposable plastic medical devices for both human and animal health, in addition to food supplements. The company's diverse product portfolio addresses numerous therapeutic categories, including cardiology, gastroenterology, pain management, cough and cold remedies, immunology and dermatology, respiratory conditions (like asthma), neurology and psychiatry, urology, and gynecology. Key products include Carsil for gastrointestinal issues, the analgesic Tempalgin, Tabex for smoking cessation, Tribestan to support sexual system functions, Broncholytin for coughs, the common pain reliever Analgin, Nivalin for peripheral nervous system disorders, and Methylprednisolon for severe allergies and critical medical situations. Beyond its core pharmaceutical business, Sopharma AD engages in a variety of other ventures. These include providing secondary packaging services for pharmaceuticals, leasing real estate, and operating in the retail sector for medicines and medical equipment. The company also handles the cultivation, collection, and trade of herbs and medicinal plants. Furthermore, it is involved in the trading, transport, and packaging of radioactive materials and nuclear equipment for medical applications, as well as household electronics and electrical equipment. Sopharma AD also offers market and public opinion research, provides franchising and know-how, and participates in various consulting and non-pharmaceutical activities, such as the production of veterinary vaccines and infusion solutions.
IPO date
Jan 20, 1998
Employees
4,770
Domiciled in
BG
Incorporated in
BG

Valuation

Title
BGN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT